<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961764</url>
  </required_header>
  <id_info>
    <org_study_id>CMO-US-ID-0476</org_study_id>
    <nct_id>NCT02961764</nct_id>
  </id_info>
  <brief_title>Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)</brief_title>
  <official_title>A Pragmatic Trial Designed to Evaluate a New Critical Pathway for Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate a new critical pathway (use of guideline-based patient
      identification criteria and for those who meet these criteria, use of dalbavancin) for the
      treatment of ABSSSI compared to usual care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Total Admitted Hospital Days</measure>
    <time_frame>44 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Infection-related Total Admitted Hospital Days</measure>
    <time_frame>44 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Admission Rate at Initial Episode of Care</measure>
    <time_frame>Initial Care: 14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency Department (ED) Length of Stay at Initial Episode of Care</measure>
    <time_frame>Initial Care: 14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infection-related Major Surgical Interventions that Required Operating Room Time</measure>
    <time_frame>44 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infection-related Hospitalizations</measure>
    <time_frame>44 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infection-related Hospitalizations during Initial Care and Follow-up that Resulted in Admission to Intensive Care Unit</measure>
    <time_frame>44 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of All Cause Hospitalizations in the 30 Days post Discharge from the Hospital or Release from the ED</measure>
    <time_frame>Follow-up: 30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infection-related ED Visits</measure>
    <time_frame>44 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infection-related Outpatient Healthcare Visits</measure>
    <time_frame>44 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of a Peripherally-Inserted Central Catheter (PICC) Line or Central Line to Administer Antibiotic Therapy</measure>
    <time_frame>44 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infection-related Healthcare Visits due to PICC Line or Central Line used to Administer Antibiotic Therapy</measure>
    <time_frame>44 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>44 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction with Care as Assessed by a 21-Item Questionnaire</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days with Work and Productivity Loss Assessed by the 6-Item Work Productivity and Activity Impairment Specific Health Problem (WPAI:SHP) Questionnaire</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health-related Quality of Life (HRQoL) Assessed by the Short Form 12 (SF-12) 12-Item Patient Questionnaire</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">322</enrollment>
  <condition>Acute Bacterial Skin and Skin Structure Infections</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New Critical Pathway</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalbavancin</intervention_name>
    <description>Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.</description>
    <arm_group_label>New Critical Pathway</arm_group_label>
    <other_name>DalvanceÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presents to the Emergency Department (ED) and meets the clinical definition for Acute
             Bacterial Skin and Skin Structure Infections (ABSSSI)

          -  Known or suspected gram-positive infection.

        Exclusion Criteria:

          -  Known or suspected gram-negative infections, anaerobic infections, or fungemia

          -  Known or suspected infections that are severe, life threatening or are not included in
             the ABSSSI Food and Drug Administration (FDA) guidance

          -  Injection drug users with a fever

          -  Severe neurological disorder leading to immobility or confined to a wheelchair

          -  Bilateral Lower extremity involvement of the suspected infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Gillard</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Registration Team</last_name>
    <phone>1-800-347-4500</phone>
    <email>IR-CTRegistration@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maricopa Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Olive View-UCLA Medical Center</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Truman Medical Centers</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://allerganclinicaltrials.com</url>
    <description>More Information</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Critical Pathways</keyword>
  <keyword>Health Facilities</keyword>
  <keyword>Clinical Protocols</keyword>
  <keyword>Patient Satisfaction</keyword>
  <keyword>Absenteeism</keyword>
  <keyword>Anti-Bacterial Agents</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Economics, Medical</keyword>
  <keyword>Health Resources</keyword>
  <keyword>Health resource utilization</keyword>
  <keyword>Acute bacterial skin and skin structure infection (ABSSSI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalbavancin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

